NCT01213472 - Evaluation of a New Anti-cancer Immunotherapy in Patients With Non-operable and Progressing Metastatic Cutaneous Melanoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 31, 2011

Primary Completion Date

April 17, 2018

Study Completion Date

April 17, 2018

Conditions

Melanoma

Interventions

BIOLOGICAL

GSK Biologicals' 2241658A Antigen-Specific Cancer Immunotherapeutic (ASCI)

Up to 24 intramuscular administrations

Trial Locations (24)

1211

GSK Investigational Site, Geneva

2060

GSK Investigational Site, North Sydney

4102

GSK Investigational Site, Woolloongabba

8091

GSK Investigational Site, Zurich

13385

GSK Investigational Site, Marseille

16132

GSK Investigational Site, Genoa

20132

GSK Investigational Site, Milan

20133

GSK Investigational Site, Milan

20141

GSK Investigational Site, Milan

23538

GSK Investigational Site, Lübeck

30625

GSK Investigational Site, Hanover

34295

GSK Investigational Site, Montpellier

44093

GSK Investigational Site, Nantes

53100

GSK Investigational Site, Siena

69120

GSK Investigational Site, Heidelberg

75006

GSK Investigational Site, Paris

79104

GSK Investigational Site, Freiburg im Breisgau

A-8036

GSK Investigational Site, Graz

1081 HV

GSK Investigational Site, Amsterdam

6229 HX

GSK Investigational Site, Maastricht

3075 EA

GSK Investigational Site, Rotterdam

CM1 7ET

GSK Investigational Site, Chelmsford

LE1 5WW

GSK Investigational Site, Leicester

SO16 6YD

GSK Investigational Site, Southampton